Skip to main content
Premium Trial:

Request an Annual Quote

GT s December 2000


GT’s December 2000 issue cover story asked if ABI’s MALDI TOF/TOF mass-spec instrument would be key to Celera’s success in proteomics. A year later, it’s still unclear whether the instrument will live up to its promised throughput.

Scott Patterson, who has since been appointed vice president for proteomics at Celera, has installed a platform that combines a liquid chromatography-based approach for separating proteins with the MALDI TOF/TOF. Patterson recently told ProteoMonitor editor John MacNeil: “I think we had targets and milestones which we set and we’re meeting those.” What exactly were those milestones? Patterson declines to say.

A feature article in the same issue asked, “What the Heck is Hyseq Up To?” The answer, in part, was “fighting a patent dispute with Affymetrix.” At the time, Hyseq chairman George Rathmann told GT that resolving that battle was on his short list. Looks like he can check that one off: In late October, Affy and Hyseq announced that they had dropped their weapons and, of all things, formed a joint venture. What’s more, it appears that Radoje Drmanac’s persistence paid off. The inventor of Hyseq’s sequencing by hybridization technology will now head up a spinoff, Callida Genomics, that will, among other things, attempt to commercialize a high-speed DNA sequencing chip.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.